Hemogenyx Pharmaceuticals Current Ratio vs. Current Valuation
| HOPHF Stock | USD 0 0.00 0.00% |
For Hemogenyx Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hemogenyx Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hemogenyx Pharmaceuticals Plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hemogenyx Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hemogenyx Pharmaceuticals Plc over time as well as its relative position and ranking within its peers.
Hemogenyx |
Hemogenyx Pharmaceuticals Current Valuation vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Hemogenyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hemogenyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Hemogenyx Pharmaceuticals Plc is one of the top stocks in current ratio category among its peers. It also is rated as one of the top companies in current valuation category among its peers reporting about 403,907 of Current Valuation per Current Ratio. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemogenyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Hemogenyx Current Valuation vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Hemogenyx Pharmaceuticals |
| = | 20.23 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Hemogenyx Pharmaceuticals |
| = | 8.17 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Hemogenyx Current Valuation vs Competition
Hemogenyx Pharmaceuticals Plc is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 3.09 Billion. Hemogenyx Pharmaceuticals adds roughly 8.17 Million in current valuation claiming only tiny portion of stocks in Biotechnology industry.
Hemogenyx Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Hemogenyx Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hemogenyx Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Hemogenyx Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Hemogenyx Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was founded in 2012 and is headquartered in London, the United Kingdom. Hemogenyx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Hemogenyx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Hemogenyx Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hemogenyx Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hemogenyx Pharmaceuticals' important profitability drivers and their relationship over time.
Use Hemogenyx Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hemogenyx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hemogenyx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Hemogenyx Pharmaceuticals Pair Trading
Hemogenyx Pharmaceuticals Plc Pair Trading Analysis
The ability to find closely correlated positions to Hemogenyx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hemogenyx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hemogenyx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hemogenyx Pharmaceuticals Plc to buy it.
The correlation of Hemogenyx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hemogenyx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hemogenyx Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hemogenyx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Hemogenyx Pharmaceuticals position
In addition to having Hemogenyx Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aircraft Thematic Idea Now
Aircraft
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Aircraft theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aircraft Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Hemogenyx Pink Sheet
To fully project Hemogenyx Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Hemogenyx Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Hemogenyx Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.